Information Provided By: 
Fly News Breaks for February 6, 2020
LGND
Feb 6, 2020 | 08:33 EDT
Benchmark analyst Robert Wasserman initiated coverage of Ligand with a Buy rating and $135 price target. Ligand has over 110 partners involved in more than 200 clinical programs, according to Wasserman, who said he views the stock as a "safer way to play the growing biotechnology sector." The company provides building block compounds that pharmaceutical makers use to discover and develop therapeutic drugs and has assembled a large portfolio of fully-funded programs, added Wasserman, who cites the company's multiple "shots on goal."
News For LGND From the Last 2 Days
There are no results for your query LGND
